Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: $6.50 to $6.78
• 50-Day Range: $4.26 to $6.99
• 52-Week Range: $2.30 to $7.39
• Volume: 412,655 shs
• Average Volume: 1.15 million shs
• Market Capitalization: $664.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.56
• Consensus Rating: Buy

Trevi Therapeutics Stock Analysis - MarketRank™

Trevi Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 272nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.7 / 5
• Analyst Rating: Buy

Consensus Rating

Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Trevi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevi Therapeutics is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevi Therapeutics is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Trevi Therapeutics has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.17% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevi Therapeutics does not currently pay a dividend.

Dividend Growth

Trevi Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.17% of the float of Trevi Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Trevi Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevi Therapeutics has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.18

News Sentiment

Trevi Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Trevi Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 8 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $583,493.00 in company stock.

Percentage Held by Insiders

24.37% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRVI Stock Analysis - Frequently Asked Questions

How have TRVI shares performed this year?

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI shares have increased by 61.2% and is now trading at $6.64.
View the best growth stocks for 2025 here.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01.
Read the conference call transcript.

When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.17%), Oppenheimer & Co. Inc. (0.10%), Rhumbline Advisers (0.09%) and Vontobel Holding Ltd. (0.03%). Insiders that own company stock include Tpg Gp A, Llc, David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini.
View institutional ownership trends.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVI
• CIK: 1563880
• Web: www.trevitherapeutics.com
• Phone: (203) 304-2499
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.56
• High Stock Price Target: $29.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +164.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,070,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.31%
• Return on Assets: -57.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.38
• Quick Ratio: 7.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 5.15

Miscellaneous

• Outstanding Shares: 99,893,000
• Free Float: 58,134,000
• Market Cap: $663.29 million
• Optionable: Optionable
• Beta: 0.62